<?xml version="1.0"  ?><!DOCTYPE pmc-articleset PUBLIC "-//NLM//DTD ARTICLE SET 2.0//EN" "https://dtd.nlm.nih.gov/ncbi/pmc/articleset/nlm-articleset-2.0.dtd"><pmc-articleset><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" article-type="brief-report" xml:lang="en" dtd-version="1.4"><!--The publisher of this article does not allow downloading of the full text in XML form.--><front><journal-meta><journal-id journal-id-type="nlm-ta">Antimicrob Agents Chemother</journal-id><journal-id journal-id-type="iso-abbrev">Antimicrob. Agents Chemother</journal-id><journal-id journal-id-type="pmc-domain-id">82</journal-id><journal-id journal-id-type="pmc-domain">aac</journal-id><journal-id journal-id-type="publisher-id">AAC</journal-id><journal-title-group><journal-title>Antimicrobial Agents and Chemotherapy</journal-title></journal-title-group><issn pub-type="ppub">0066-4804</issn><issn pub-type="epub">1098-6596</issn><publisher><publisher-name>American Society for Microbiology (ASM)</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmcid">PMC7269476</article-id><article-id pub-id-type="pmcid-ver">PMC7269476.1</article-id><article-id pub-id-type="pmcaid">7269476</article-id><article-id pub-id-type="pmcaiid">7269476</article-id><article-id pub-id-type="pmid">32253214</article-id><article-id pub-id-type="doi">10.1128/AAC.00342-20</article-id><article-id pub-id-type="publisher-id">00342-20</article-id><article-version article-version-type="pmc-version">1</article-version><article-categories><subj-group subj-group-type="heading"><subject>Pharmacology</subject></subj-group></article-categories><title-group><article-title>Oral Fosfomycin Treatment for Enterococcal Urinary Tract Infections in a Dynamic <italic toggle="yes">In Vitro</italic> Model</article-title><alt-title alt-title-type="running-head">Fosfomycin Efficacy for Enterococcal UTIs</alt-title><alt-title alt-title-type="short-authors">Abbott et al.</alt-title></title-group><contrib-group><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0001-6590-6127</contrib-id><name name-style="western"><surname>Abbott</surname><given-names initials="IJ">Iain J.</given-names></name><xref ref-type="aff" rid="aff1"><sup>a</sup></xref><xref ref-type="aff" rid="aff2"><sup>b</sup></xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>van Gorp</surname><given-names initials="E">Elke</given-names></name><xref ref-type="aff" rid="aff2"><sup>b</sup></xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>van der Meijden</surname><given-names initials="A">Aart</given-names></name><xref ref-type="aff" rid="aff2"><sup>b</sup></xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Wijma</surname><given-names initials="RA">Rixt A.</given-names></name><xref ref-type="aff" rid="aff2"><sup>b</sup></xref><xref ref-type="aff" rid="aff3"><sup>c</sup></xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Meletiadis</surname><given-names initials="J">Joseph</given-names></name><xref ref-type="aff" rid="aff4"><sup>d</sup></xref></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0001-6218-435X</contrib-id><name name-style="western"><surname>Roberts</surname><given-names initials="JA">Jason A.</given-names></name><xref ref-type="aff" rid="aff5"><sup>e</sup></xref><xref ref-type="aff" rid="aff6"><sup>f</sup></xref><xref ref-type="aff" rid="aff7"><sup>g</sup></xref><xref ref-type="aff" rid="aff8"><sup>h</sup></xref></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0001-6736-4149</contrib-id><name name-style="western"><surname>Mouton</surname><given-names initials="JW">Johan W.</given-names></name><xref ref-type="aff" rid="aff2"><sup>b</sup></xref></contrib><contrib contrib-type="author" corresp="yes"><name name-style="western"><surname>Peleg</surname><given-names initials="AY">Anton Y.</given-names></name><xref ref-type="aff" rid="aff1"><sup>a</sup></xref><xref ref-type="aff" rid="aff9"><sup>i</sup></xref></contrib><aff id="aff1"><label>a</label><addr-line>Department of Infectious Diseases, The Alfred Hospital and Central Clinical School, Monash University, Melbourne, Victoria, Australia</addr-line></aff><aff id="aff2"><label>b</label><addr-line>Department of Medical Microbiology and Infectious Diseases, Research and Development Unit, Erasmus Medical Centre, Rotterdam, The Netherlands</addr-line></aff><aff id="aff3"><label>c</label><addr-line>Department of Hospital Pharmacy, Erasmus University Medical Centre, Rotterdam, The Netherlands</addr-line></aff><aff id="aff4"><label>d</label><addr-line>Clinical Microbiology Laboratory, Attikon University Hospital, Medical School, National and Kapodistrian University of Athens, Athens, Greece</addr-line></aff><aff id="aff5"><label>e</label><addr-line>University of Queensland Centre for Clinical Research, Faculty of Medicine, The University of Queensland, Brisbane, Australia</addr-line></aff><aff id="aff6"><label>f</label><addr-line>School of Pharmacy, Centre for Translational Anti-infective Pharmacodynamics, The University of Queensland, Brisbane, Australia</addr-line></aff><aff id="aff7"><label>g</label><addr-line>Department of Intensive Care Medicine, Royal Brisbane and Women&#8217;s Hospital, Brisbane, Australia</addr-line></aff><aff id="aff8"><label>h</label><addr-line>Division of Anaesthesiology Critical Care Emergency and Pain Medicine, N&#238;mes University Hospital, University of Montpellier, N&#238;mes, France</addr-line></aff><aff id="aff9"><label>i</label><addr-line>Infection and Immunity Program, Monash Biomedicine Discovery Institute, Department of Microbiology, Monash University, Clayton, Victoria, Australia</addr-line></aff></contrib-group><author-notes><corresp id="cor1">Address correspondence to Anton Y. Peleg, <email>anton.peleg@monash.edu</email>.</corresp><fn fn-type="other"><p><bold>Citation</bold> Abbott IJ, van Gorp E, van der Meijden A, Wijma RA, Meletiadis J, Roberts JA, Mouton JW, Peleg AY. 2020. Oral fosfomycin treatment for enterococcal urinary tract infections in a dynamic <italic toggle="yes">in vitro</italic> model. Antimicrob Agents Chemother 64:e00342-20. <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://doi.org/10.1128/AAC.00342-20">https://doi.org/10.1128/AAC.00342-20</ext-link>.</p></fn></author-notes><pub-date pub-type="epreprint"><day>6</day><month>4</month><year>2020</year></pub-date><pub-date pub-type="epub"><day>21</day><month>5</month><year>2020</year></pub-date><pub-date pub-type="collection"><month>6</month><year>2020</year></pub-date><volume>64</volume><issue>6</issue><issue-id pub-id-type="pmc-issue-id">358919</issue-id><elocation-id>e00342-20</elocation-id><history><date date-type="received"><day>20</day><month>2</month><year>2020</year></date><date date-type="rev-request"><day>19</day><month>3</month><year>2020</year></date><date date-type="accepted"><day>26</day><month>3</month><year>2020</year></date></history><pub-history><event event-type="pmc-release"><date><day>21</day><month>11</month><year>2020</year></date></event><event event-type="pmc-live"><date><day>21</day><month>11</month><year>2020</year></date></event><event event-type="pmc-last-change"><date iso-8601-date="2020-11-21 00:41:34.877"><day>21</day><month>11</month><year>2020</year></date></event></pub-history><permissions><copyright-statement>Copyright &#169; 2020 American Society for Microbiology.</copyright-statement><copyright-year>2020</copyright-year><copyright-holder>American Society for Microbiology</copyright-holder><license xmlns:xlink="http://www.w3.org/1999/xlink" license-type="asm" xlink:href="https://doi.org/10.1128/ASMCopyrightv2"><license-p><ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1128/ASMCopyrightv2">All Rights Reserved</ext-link>.</license-p></license></permissions><self-uri xmlns:xlink="http://www.w3.org/1999/xlink" content-type="pmc-pdf" xlink:href="AAC.00342-20.pdf"/><self-uri xmlns:xlink="http://www.w3.org/1999/xlink" content-type="pdf" xlink:href="AAC.00342-20.pdf"/><abstract abstract-type="precis"><p>There are limited treatment options for enterococcal urinary tract infections, especially vancomycin-resistant <italic toggle="yes">Enterococcus</italic> (VRE). Oral fosfomycin is a potential option, although limited data are available guiding dosing and susceptibility. We undertook pharmacodynamic profiling of fosfomycin against <named-content content-type="genus-species">E. faecalis</named-content> and <named-content content-type="genus-species">E. faecium</named-content> isolates using a dynamic <italic toggle="yes">in vitro</italic> bladder infection model. Eighty-four isolates underwent fosfomycin agar dilution susceptibility testing (<named-content content-type="genus-species">E. faecalis</named-content> MIC<sub>50/90</sub> 32/64&#8201;&#956;g/ml; <named-content content-type="genus-species">E. faecium</named-content> MIC<sub>50/90</sub> 64/128&#8201;&#956;g/ml).</p></abstract><abstract><title>ABSTRACT</title><p>There are limited treatment options for enterococcal urinary tract infections, especially vancomycin-resistant <italic toggle="yes">Enterococcus</italic> (VRE). Oral fosfomycin is a potential option, although limited data are available guiding dosing and susceptibility. We undertook pharmacodynamic profiling of fosfomycin against <named-content content-type="genus-species">E. faecalis</named-content> and <named-content content-type="genus-species">E. faecium</named-content> isolates using a dynamic <italic toggle="yes">in vitro</italic> bladder infection model. Eighty-four isolates underwent fosfomycin agar dilution susceptibility testing (<named-content content-type="genus-species">E. faecalis</named-content> MIC<sub>50/90</sub> 32/64&#8201;&#956;g/ml; <named-content content-type="genus-species">E. faecium</named-content> MIC<sub>50/90</sub> 64/128&#8201;&#956;g/ml). Sixteen isolates (including <named-content content-type="genus-species">E. faecalis</named-content> ATCC 29212 and <named-content content-type="genus-species">E. faecium</named-content> ATCC 35667) were chosen to reflect the MIC range and tested in the bladder infection model with synthetic human urine (SHU). Under drug-free conditions, <named-content content-type="genus-species">E. faecium</named-content> demonstrated greater growth restriction in SHU compared to <named-content content-type="genus-species">E. faecalis</named-content> (<named-content content-type="genus-species">E. faecium</named-content> maximal growth 5.8&#8201;&#177;&#8201;0.6 log<sub>10</sub> CFU/ml; <named-content content-type="genus-species">E. faecalis</named-content> 8.0&#8201;&#177;&#8201;1.0 log<sub>10</sub> CFU/ml). Isolates were exposed to high and low fosfomycin urinary concentrations after a single dose, and after two doses given over two days with low urinary concentration exposure. Simulated concentrations closely matched the target (bias 2.3%). <named-content content-type="genus-species">E. faecalis</named-content> isolates required greater fosfomycin exposure for 3 log<sub>10</sub> kill from the starting inoculum compared with <named-content content-type="genus-species">E. faecium</named-content>. The &#402;AUC<sub>0-72</sub>/MIC and &#402;%T &gt; MIC<sub>0-72</sub> for <named-content content-type="genus-species">E. faecalis</named-content> were 672 and 70%, compared to 216 and 51% for <named-content content-type="genus-species">E. faecium</named-content>, respectively. There was no rise in fosfomycin MIC postexposure. Two doses of fosfomycin with low urinary concentrations resulted in equivalent growth inhibition to a single dose with high urinary concentrations. With this urinary exposure, fosfomycin was effective in promoting suppression of regrowth (&gt;3 log<sub>10</sub> kill) in the majority of isolates.</p></abstract><kwd-group><title>KEYWORDS</title><kwd><italic toggle="yes">Enterococcus</italic></kwd><kwd>fosfomycin</kwd><kwd>in vitro modelling</kwd><kwd>pharmacodynamics</kwd><kwd>pharmacokinetics</kwd><kwd>synthetic human urine</kwd><kwd>urinary tract infection</kwd><kwd>vancomycin resistance</kwd></kwd-group><counts><fig-count count="6"/><table-count count="2"/><equation-count count="0"/><ref-count count="60"/><page-count count="14"/><word-count count="8847"/></counts><custom-meta-group><custom-meta><meta-name>pmc-status-qastatus</meta-name><meta-value>0</meta-value></custom-meta><custom-meta><meta-name>pmc-status-live</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-status-embargo</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-status-released</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-open-access</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-olf</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-manuscript</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-legally-suppressed</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-pdf</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-supplement</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-pdf-only</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-suppress-copyright</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-real-version</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-scanned-article</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-preprint</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-in-epmc</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>cover-date</meta-name><meta-value>June 2020</meta-value></custom-meta></custom-meta-group></article-meta></front></article></pmc-articleset>